Compare

Nanobiotix/$NBTX

1D1W1M3M6MYTD1Y5YMAX

About Nanobiotix

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
Ticker
$NBTX
Sector
Health
Primary listing
NASDAQ
Employees
98
Headquarters
Paris, France
Website
www.nanobiotix.com

Nanobiotix Metrics

BasicAdvanced
$1.5B
-
-$1.22
0.59
-

What the Analysts think about Nanobiotix

Analyst ratings (Buy, Hold, Sell) for Nanobiotix stock.
Analyst projections of the future price of Nanobiotix stock.

Bulls say / Bears say

In a difficult recurrent lung-cancer setting, all 24 patients completed treatment and the study reported 79% one-year locoregional control and 70% one-year overall survival. No severe adverse events were attributed to JNJ-1900 or its injection, although the results are from a small Phase 1 study. (GlobeNewswire)
Early CONVERGE results in stage 3 lung cancer showed a 57% complete response rate and an 86% overall response rate after the full treatment regimen. If confirmed in a larger group, the responses could support testing JNJ-1900 in an earlier disease setting. (SEC)
The FDA-cleared NANORAY-312 amendment moves the Phase 3 trial towards a final analysis with fewer events than originally planned, which could bring an important head-and-neck cancer result forward. Separately, Nanobiotix reported €110.9 million in cash at June 2026 and expects it to fund operations into 2029. (GlobeNewswire, SEC)
The striking CONVERGE response figures came from only seven patients and were investigator-reported after treatment with chemoradiotherapy and durvalumab as well as JNJ-1900. Such preliminary results may not hold up in a larger controlled analysis. (SEC)
The Phase 1 re-irradiation study reported Grade 3 radiotherapy-related events in a third of patients and fatal radiotherapy-related events in two of 24. These harms matter even though investigators did not attribute severe events to JNJ-1900 or the injection itself. (GlobeNewswire)
Nanobiotix remains loss-making: its first-half 2026 net loss was €34.3 million, while revenue and other income fell to €5.6 million. The May share offering raised about €86 million but issued new shares and warrants, diluting existing holders; the company also says further funding may be needed if milestones or other financing do not cover its plans. (SEC, BioSpace)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.

Nanobiotix Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Nanobiotix Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.